These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 24880619)

  • 81. Effect of a single-cycle alternative dosing regimen for rituximab for recalcitrant pemphigus: a case series of 9 patients.
    Matsukura S; Knowles SR; Walsh S; Shear NH
    Arch Dermatol; 2012 Jun; 148(6):734-9. PubMed ID: 22351790
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Prevention of Orbitopathy by Oral or Intravenous Steroid Prophylaxis in Short Duration Graves' Disease Patients Undergoing Radioiodine Ablation: A Prospective Randomized Control Trial Study.
    Vannucchi G; Covelli D; Campi I; Currò N; Dazzi D; Rodari M; Pepe G; Chiti A; Guastella C; Lazzaroni E; Salvi M
    Thyroid; 2019 Dec; 29(12):1828-1833. PubMed ID: 31860407
    [No Abstract]   [Full Text] [Related]  

  • 83. The therapeutic outcome to intravenous steroid therapy for active Graves' orbitopathy is influenced by the time of response but not polymorphisms of the glucocorticoid receptor.
    Vannucchi G; Covelli D; Campi I; Origo D; Currò N; Cirello V; Dazzi D; Beck-Peccoz P; Salvi M
    Eur J Endocrinol; 2014 Jan; 170(1):55-61. PubMed ID: 24128430
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Effects of rituximab in two patients with dysferlin-deficient muscular dystrophy.
    Lerario A; Cogiamanian F; Marchesi C; Belicchi M; Bresolin N; Porretti L; Torrente Y
    BMC Musculoskelet Disord; 2010 Jul; 11():157. PubMed ID: 20618995
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Rituximab efficiently depletes increased CD20-expressing T cells in multiple sclerosis patients.
    Palanichamy A; Jahn S; Nickles D; Derstine M; Abounasr A; Hauser SL; Baranzini SE; Leppert D; von Büdingen HC
    J Immunol; 2014 Jul; 193(2):580-586. PubMed ID: 24928997
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Fractionated subcutaneous rituximab is well-tolerated and preserves CD20 expression on tumor cells in patients with chronic lymphocytic leukemia.
    Aue G; Lindorfer MA; Beum PV; Pawluczkowycz AW; Vire B; Hughes T; Taylor RP; Wiestner A
    Haematologica; 2010 Feb; 95(2):329-32. PubMed ID: 19679883
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjögren's syndrome.
    Seror R; Sordet C; Guillevin L; Hachulla E; Masson C; Ittah M; Candon S; Le Guern V; Aouba A; Sibilia J; Gottenberg JE; Mariette X
    Ann Rheum Dis; 2007 Mar; 66(3):351-7. PubMed ID: 16950808
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Treatment by rituximab on six Grave's ophthalmopathies resistant to corticosteroids.
    Précausta F; Arsène S; Renoult-Pierre P; Laure B; Crinière L; Pisella PJ
    Ann Endocrinol (Paris); 2017 Feb; 78(1):20-26. PubMed ID: 28185649
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Lack of efficacy of rituximab in Wegener's granulomatosis with refractory granulomatous manifestations.
    Aries PM; Hellmich B; Voswinkel J; Both M; Nölle B; Holl-Ulrich K; Lamprecht P; Gross WL
    Ann Rheum Dis; 2006 Jul; 65(7):853-8. PubMed ID: 16269425
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Comparison of the effectiveness and tolerability of intravenous or oral glucocorticoids associated with orbital radiotherapy in the management of severe Graves' ophthalmopathy: results of a prospective, single-blind, randomized study.
    Marcocci C; Bartalena L; Tanda ML; Manetti L; Dell'Unto E; Rocchi R; Barbesino G; Mazzi B; Bartolomei MP; Lepri P; Cartei F; Nardi M; Pinchera A
    J Clin Endocrinol Metab; 2001 Aug; 86(8):3562-7. PubMed ID: 11502779
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Rituximab in refractory ophthalmic Wegener's granulomatosis: PR3 titers may predict relapse, but repeat treatment can be effective.
    Joshi L; Lightman SL; Salama AD; Shirodkar AL; Pusey CD; Taylor SR
    Ophthalmology; 2011 Dec; 118(12):2498-503. PubMed ID: 21907416
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Induction of thyroid remission using rituximab in a patient with type 3 autoimmune polyglandular syndrome including Graves' disease and type 1 diabetes mellitus: a case report.
    Kurozumi A; Okada Y; Arao T; Narisawa M; Torimoto K; Yamamoto S; Tanaka Y
    Endocr J; 2015; 62(1):69-75. PubMed ID: 25273396
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Severe unilateral orbitopathy in a patient with Hashimoto's thyroiditis - a case report.
    Cyranska-Chyrek E; Olejarz M; Szczepanek-Parulska E; Stajgis P; Pioch A; Ruchala M
    BMC Ophthalmol; 2019 Jan; 19(1):9. PubMed ID: 30621642
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Enhanced therapeutic effect of B cell-depleting anti-CD20 antibodies upon combination with in-situ dendritic cell vaccination in advanced lymphoma.
    Manzur S; Cohen S; Haimovich J; Hollander N
    Clin Exp Immunol; 2012 Dec; 170(3):291-9. PubMed ID: 23121670
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Benefit from B-lymphocyte depletion using the anti-CD20 antibody rituximab in chronic fatigue syndrome. A double-blind and placebo-controlled study.
    Fluge Ø; Bruland O; Risa K; Storstein A; Kristoffersen EK; Sapkota D; Næss H; Dahl O; Nyland H; Mella O
    PLoS One; 2011; 6(10):e26358. PubMed ID: 22039471
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Rituximab-CD20 complexes are shaved from Z138 mantle cell lymphoma cells in intravenous and subcutaneous SCID mouse models.
    Li Y; Williams ME; Cousar JB; Pawluczkowycz AW; Lindorfer MA; Taylor RP
    J Immunol; 2007 Sep; 179(6):4263-71. PubMed ID: 17785867
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Randomized controlled trial of rituximab in patients with Graves' orbitopathy.
    Stan MN; Garrity JA; Carranza Leon BG; Prabin T; Bradley EA; Bahn RS
    J Clin Endocrinol Metab; 2015 Feb; 100(2):432-41. PubMed ID: 25343233
    [TBL] [Abstract][Full Text] [Related]  

  • 98. The Efficacy of Rituximab Combined with 131I for Ophthalmic Outcomes of Graves' Ophthalmopathy Patients.
    Li J; Xiao Z; Hu X; Li Y; Zhang X; Zhang S; Gong W; Zhao J; Ye X
    Pharmacology; 2017; 99(3-4):144-152. PubMed ID: 28049190
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves' orbitopathy: a randomized controlled study.
    Salvi M; Vannucchi G; Currò N; Campi I; Covelli D; Dazzi D; Simonetta S; Guastella C; Pignataro L; Avignone S; Beck-Peccoz P
    J Clin Endocrinol Metab; 2015 Feb; 100(2):422-31. PubMed ID: 25494967
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Bayesian network analysis of drug treatment strategies for thyroid associated ophthalmopathy.
    Jinhai Y; Qassem AAM; Qi J; Chao X; Anan W; Qi X; Hongfei L; Dequan D
    Int Ophthalmol; 2024 Aug; 44(1):339. PubMed ID: 39097840
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.